Liang Tianwei, Chen Xiaoqing, de Hoog G Sybren, Li Lulu, Wang Lingqi, Wan Zhe, Yu Jin, Li Ruoyu, Song Yinggai
Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China.
Research Center for Medical Mycology, Peking University, Beijing, China.
Mycoses. 2025 Jan;68(1):e70020. doi: 10.1111/myc.70020.
Microsporum canis, a dermatophyte commonly associated with pets, is a leading cause of severe tinea capitis. The increasing prevalence of antifungal resistance among dermatophytes poses a significant global health challenge.
This study aims to define the updated antifungal susceptibility profile of M. canis to enhance treatment strategies for dermatophyte infections.
This study analysed 348 M. canis isolates from mainland China for their susceptibility to 11 antifungal agents, following the CLSI M38-A3 guidelines. Additionally, we investigated the susceptibility of M. canis to antifungal agents and analysed the correlation between in vitro drug susceptibility and clinical outcomes in 54 cases of tinea capitis.
The majority of strains showed low MICs to all 11 drugs. We described the upper limits of wild-type (WT) minimal inhibitory concentrations (UL-WT) for 10 of these agents; however, no clear resistance patterns were identified through MIC distribution analysis. Notably, fluconazole had the highest MICs among the tested classes, while the novel agent olorofim showed superior activity. Resistance was detected in two strains to griseofulvin (MIC 64 μg/mL), one to fluconazole (MIC 64 μg/mL) and two to terbinafine (MIC 16 μg/mL). Although azoles and terbinafine remain effective against M. canis. Clinical outcomes indicate that terbinafine may be less effective in treating M. canis infections.
Establishing a clinical breakpoint for M. canis is urgently needed to improve treatment protocols. While azoles and griseofulvin are still recommended for M. canis infections, ongoing surveillance of dermatophyte species and their susceptibility to antifungal agents is crucial to guide treatment strategies.
犬小孢子菌是一种常见于宠物的皮肤癣菌，是严重头癣的主要病因。皮肤癣菌中抗真菌耐药性的日益普遍对全球健康构成了重大挑战。
本研究旨在确定犬小孢子菌最新的抗真菌药敏谱，以加强皮肤癣菌感染的治疗策略。
本研究按照CLSI M38-A3指南，分析了来自中国大陆的348株犬小孢子菌对11种抗真菌药物的敏感性。此外，我们调查了犬小孢子菌对抗真菌药物的敏感性，并分析了54例头癣患者的体外药敏与临床结果之间的相关性。
大多数菌株对所有11种药物的最低抑菌浓度都很低。我们描述了其中10种药物的野生型（WT）最低抑菌浓度上限（UL-WT）；然而，通过最低抑菌浓度分布分析未发现明确的耐药模式。值得注意的是，在测试的类别中，氟康唑的最低抑菌浓度最高，而新型药物奥拉氟表现出更强的活性。检测到2株对灰黄霉素耐药（最低抑菌浓度为64μg/mL），1株对氟康唑耐药（最低抑菌浓度为64μg/mL），2株对特比萘芬耐药（最低抑菌浓度为16μg/mL）。尽管唑类和特比萘芬对犬小孢子菌仍然有效。临床结果表明，特比萘芬在治疗犬小孢子菌感染方面可能效果较差。
迫切需要为犬小孢子菌建立临床断点以改进治疗方案。虽然仍推荐唑类和灰黄霉素用于犬小孢子菌感染，但持续监测皮肤癣菌种类及其对抗真菌药物的敏感性对于指导治疗策略至关重要。
